 | Up a level |
Pabst, Thomas; Papayannidis, Cristina; Demirkan, Fatih; Doronin, Vadim; Fogliatto, Laura M; Guttke, Christina; Gyan, Emmanuel; Hamad, Nada; Herrera, Pilar; Hultberg, Anna; Jacobs, Julie; Johnson, Amy J; Langlois, Angélique; Ma, Xuewen; Martinelli, Giovanni; Arnan, Montserrat; Müller, Rouven; Nottage, Kerri; Ofran, Yishai; Özcan, Muhit; ... (2023). Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. The Lancet. Haematology, 10(11), e902-e912. Elsevier 10.1016/S2352-3026(23)00207-7
Pabst, Thomas; Vey, Norbert; Adès, Lionel; Bacher, Ulrike; Bargetzi, Mario; Fung, Samson; Gaidano, Gianluca; Gandini, Domenica; Hultberg, Anna; Johnson, Amy; Ma, Xuewen; Müller, Rouven; Nottage, Kerri; Papayannidis, Cristina; Recher, Christian; Riether, Carsten; Shah, Priya; Tryon, Jeffrey; Xiu, Liang and Ochsenbein, Adrian F (2023). Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Haematologica - the hematology journal, 108(7), pp. 1793-1802. Ferrata-Storti Foundation 10.3324/haematol.2022.281563
Trabanelli, Sara; Chevalier, Mathieu F; Martinez-Usatorre, Amaia; Gomez-Cadena, Alejandra; Salomé, Bérengère; Lecciso, Mariangela; Salvestrini, Valentina; Verdeil, Grégory; Racle, Julien; Papayannidis, Cristina; Morita, Hideaki; Pizzitola, Irene; Grandclément, Camille; Bohner, Perrine; Bruni, Elena; Girotra, Mukul; Pallavi, Rani; Falvo, Paolo; Oppliger Leibundgut, Elisabeth; Baerlocher, Gabriela M.; ... (2017). Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature communications, 8(1), p. 593. Nature Publishing Group 10.1038/s41467-017-00678-2
